Law360, New York (November 19, 2010, 6:10 PM ET) -- Frequent qui tam plaintiff Promote Innovation LLC has accused Bristol-Myers Squibb Co. of marking its antibiotic Cefzil, its anti-anxiety medication Buspar and its cholesterol drug Pravachol with expired or inapplicable patents.
Bristol-Myers knowingly marked these accused products with three expired patents and one inapplicable patent that subsequently expired in order to deceive the public and gain a competitive advantage in the relevant marketplace, the plaintiff alleges in a complaint filed Thursday in the U.S. District Court for the Eastern District of Texas.
This false marking has...
Bristol-Myers Hit With False Marking Suit Over 3 Drugs
To view the full article, take a free trial now.
